Daily Aspirin Cuts Ovarian Cancer Risk

Share this content:
Daily Aspirin May Guard Against Ovarian Cancer
Daily Aspirin May Guard Against Ovarian Cancer

(HealthDay News) — Taking aspirin every day might lower a woman's risk of developing ovarian cancer by one-fifth, according to research published in the February issue of the Journal of the National Cancer Institute.

Researchers from the U.S. National Cancer Institute analyzed data from 12 studies that involved nearly 8,000 women with ovarian cancer and close to 12,000 women without the disease to determine how the use of aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen (Tylenol) affected the risk of ovarian cancer.

RELATED: Gynecologic Cancers Resource Center

About 18% of the women used aspirin regularly, 24% used non-aspirin NSAIDs, and 16% used acetaminophen. The researchers found that those who used aspirin daily had a 20% lower risk of ovarian cancer than those who used aspirin less than once a week. The risk of ovarian cancer was 10% lower in women who used non-aspirin NSAIDs at least once a week, compared to those who used them less often. However, this difference was not statistically significant. No link was found between acetaminophen use and ovarian cancer risk.

"Our study suggests that aspirin regimens, proven to protect against heart attack, may reduce the risk of ovarian cancer as well," Britton Trabert, of the National Cancer Institute's division of cancer epidemiology, said in a U.S. National Institutes of Health news release. 

"However intriguing our results are, they should not influence current clinical practice," she added. "Additional studies are needed to explore the delicate balance of risk and benefit for this potential chemopreventive agent, as well as studies to identify [how] aspirin may reduce ovarian cancer risk."


  1. Trabert B, Ness RB, Lo-Ciganic WH, et al. Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014;doi:10.1093/jnci/djt431.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs